UNSPSC 51261503: Indoramin

This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Z802HMY7H, chemically known as benzamide, n-(1-(2-indol-3-ylethyl)-4-piperidyl)- but generally known as indoramin, which bears US NIH Compound Identifier 33625. European Medicines Agency schedules Indoramin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08184MIG.

UNSPSC 51261503 Indoramin, a Commodity code, does not align with the recent state and local procurement activity posted under this classification. The single recent opportunity on record—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026—solicits naloxone and drug deactivation systems for community health initiatives, a pharmaceutical and medical-device procurement wholly unrelated to indoramin, which is an antihypertensive pharmaceutical. The code shows no recent activity relevant to its nominal scope.

The mismatch suggests either a data-entry error in the county's procurement system or a misclassification at tagging. State and local procurement systems occasionally cross-code opportunities, particularly when new product categories or emergency health initiatives do not map cleanly to legacy UNSPSC hierarchies. A business development professional evaluating this code should verify the actual commodity classification under which naloxone and deactivation systems are being procured—likely under a medical-supply or public-health-equipment family—rather than pursue opportunities listed here. No geographic concentration, repeat-buyer pattern, or procurement momentum can be assessed from a single misclassified opportunity.